Total hepatectomy and liver replacement (orthotopic liver transplantation) for primary hepatic malignancy

There has been a high incidence of tumor recurrence after liver transplantation for primary hepatic malignancy. Nevertheless, a small but significant palliation has been possible with this approach, even in patients who eventually died of recurrence. Two patients with incidental malignancies in their excised livers apparently have been cured. Further gains will be possible only with extremely discriminating selection of prospective recipients. © 1982 Société Internationale de Chirurgie

Liver and intestine transplantation

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/73604/1/j.1600-6135.2004.00400.x.pd

Model for end-stage liver disease (MELD) exception guidelines: Results and recommendations from the MELD exception study group and conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula

No abstract.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/55914/1/20979_ftp.pd

Outcomes of immunosuppression minimization and withdrawal early after liver transplantation

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/149209/1/ajt15205.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/149209/2/ajt15205_am.pd

The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence

Despite the success of liver transplantation, long-term complications remain, including de novo malignancies, metabolic syndrome, and the recurrence of hepatitis C virus (HCV) and hepatocellular carcinoma (HCC). The current mainstay of treatment, calcineurin inhibitors (CNIs), can also worsen posttransplant renal dysfunction, neurotoxicity, and diabetes. Clearly there is a need for better immunosuppressive agents that maintain similar rates of efficacy and renal function whilst minimizing adverse effects. The mammalian target of rapamycin (mTOR) inhibitors with a mechanism of action that is different from other immunosuppressive agents has the potential to address some of these issues. In this review we surveyed the literature for reports of the use of mTOR inhibitors in adult liver transplantation with respect to renal function, efficacy, safety, neurological symptoms, de novo tumors, and the recurrence of HCC and HCV. The results of our review indicate that mTOR inhibitors are associated with efficacy comparable to CNIs while having benefits on renal function in liver transplantation. We also consider newer dosing schedules that may limit side effects. Finally, we discuss evidence that mTOR inhibitors may have benefits in the oncology setting and in relation to HCV-related allograft fibrosis, metabolic syndrome, and neurotoxicity

Transplant Surgery Fellow Perceptions About Training and the Ensuing Job Market—Are the Right Number of Surgeons Being Trained?

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90327/1/j.1600-6143.2010.03308.x.pd

Transplant Center Regulations—A Mixed Blessing? An ASTS Council Viewpoint

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/72050/1/j.1600-6143.2008.02434.x.pd